7 minute read
May 1, 2023

A Furan-Containing Insurmountable Antagonist and Inverse Agonist of the Adenosine A2A Receptor for Parkinson’s Disease


oral A2A receptor antagonist/inverse agonist Ph. II for Parkinson’s Disease 2nd gen. A2A receptor antagonist ASPET, March 9, 2023 Kyowa Kirin Co., Ltd., Shizuoka, JP

Drug Hunter Team

Kyowa Kirin’s KW-6356, or sipagladenant , is a non-xanthine A 2A receptor intended to treat Parkinson’s disease. Unlike Kyowa Kirin’s recently US-approved neutral antagonist, istradefylline, the molecule is an [...]



Other molecules you may be interested in